vs

Side-by-side financial comparison of ARVINAS, INC. (ARVN) and OCTAVE SPECIALTY GROUP INC (OSG). Click either name above to swap in a different company.

OCTAVE SPECIALTY GROUP INC is the larger business by last-quarter revenue ($66.9M vs $41.9M, roughly 1.6× ARVINAS, INC.). OCTAVE SPECIALTY GROUP INC runs the higher net margin — -73.8% vs -83.8%, a 10.0% gap on every dollar of revenue. On growth, OCTAVE SPECIALTY GROUP INC posted the faster year-over-year revenue change (2.6% vs -59.1%). Over the past eight quarters, OCTAVE SPECIALTY GROUP INC's revenue compounded faster (16.2% CAGR vs 10.0%).

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing targeted protein degradation therapies, including PROTAC molecules, to treat cancer and rare diseases. It operates primarily in the U.S. and global biopharma markets, advancing multiple pipeline candidates through clinical trials to address unmet medical needs.

Octave Specialty Group Inc. is a specialty insurance holding company that provides tailored property and casualty insurance products. Its core business focuses on excess and surplus lines, catering to commercial and individual clients across primary North American markets with customized risk coverage solutions.

ARVN vs OSG — Head-to-Head

Bigger by revenue
OSG
OSG
1.6× larger
OSG
$66.9M
$41.9M
ARVN
Growing faster (revenue YoY)
OSG
OSG
+61.7% gap
OSG
2.6%
-59.1%
ARVN
Higher net margin
OSG
OSG
10.0% more per $
OSG
-73.8%
-83.8%
ARVN
Faster 2-yr revenue CAGR
OSG
OSG
Annualised
OSG
16.2%
10.0%
ARVN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ARVN
ARVN
OSG
OSG
Revenue
$41.9M
$66.9M
Net Profit
$-35.1M
$-29.7M
Gross Margin
Operating Margin
-104.5%
-76.7%
Net Margin
-83.8%
-73.8%
Revenue YoY
-59.1%
2.6%
Net Profit YoY
28.7%
-41.7%
EPS (diluted)
$-0.48
$-0.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARVN
ARVN
OSG
OSG
Q4 25
$66.9M
Q3 25
$41.9M
$66.6M
Q2 25
$55.0M
Q1 25
$188.8M
$62.8M
Q4 24
$59.2M
$65.2M
Q3 24
$102.4M
$70.0M
Q2 24
$76.5M
$51.0M
Q1 24
$25.3M
$49.6M
Net Profit
ARVN
ARVN
OSG
OSG
Q4 25
$-29.7M
Q3 25
$-35.1M
$-112.6M
Q2 25
$-72.7M
Q1 25
$82.9M
$-44.7M
Q4 24
$-45.1M
$-20.9M
Q3 24
$-49.2M
$-27.5M
Q2 24
$-35.2M
$-750.0K
Q1 24
$-69.4M
$20.8M
Operating Margin
ARVN
ARVN
OSG
OSG
Q4 25
-76.7%
Q3 25
-104.5%
-48.2%
Q2 25
-41.8%
Q1 25
37.8%
-24.1%
Q4 24
-98.1%
-55.5%
Q3 24
-58.9%
-29.7%
Q2 24
-63.4%
-28.9%
Q1 24
-329.2%
-6.5%
Net Margin
ARVN
ARVN
OSG
OSG
Q4 25
-73.8%
Q3 25
-83.8%
-169.1%
Q2 25
-132.3%
Q1 25
43.9%
-71.3%
Q4 24
-76.2%
-55.1%
Q3 24
-48.0%
-39.3%
Q2 24
-46.0%
-1.5%
Q1 24
-274.3%
41.9%
EPS (diluted)
ARVN
ARVN
OSG
OSG
Q4 25
$-0.82
Q3 25
$-0.48
$-2.35
Q2 25
$-1.54
Q1 25
$1.14
$-1.22
Q4 24
$-0.63
$-11.75
Q3 24
$-0.68
$-0.63
Q2 24
$-0.49
$-0.02
Q1 24
$-0.97
$0.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARVN
ARVN
OSG
OSG
Cash + ST InvestmentsLiquidity on hand
$787.6M
$146.4M
Total DebtLower is stronger
$600.0K
$117.6M
Stockholders' EquityBook value
$564.4M
$715.8M
Total Assets
$844.3M
$2.2B
Debt / EquityLower = less leverage
0.00×
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARVN
ARVN
OSG
OSG
Q4 25
$146.4M
Q3 25
$787.6M
$27.5M
Q2 25
$22.5M
Q1 25
$954.3M
$34.1M
Q4 24
$1.0B
$157.2M
Q3 24
$1.1B
$40.8M
Q2 24
$1.2B
$14.6M
Q1 24
$1.2B
$13.8M
Total Debt
ARVN
ARVN
OSG
OSG
Q4 25
$117.6M
Q3 25
$600.0K
Q2 25
Q1 25
$700.0K
Q4 24
$800.0K
$0
Q3 24
$800.0K
$518.0M
Q2 24
$900.0K
$515.0M
Q1 24
$900.0K
$512.0M
Stockholders' Equity
ARVN
ARVN
OSG
OSG
Q4 25
$715.8M
Q3 25
$564.4M
$843.4M
Q2 25
$859.8M
Q1 25
$660.1M
$852.2M
Q4 24
$561.7M
$798.4M
Q3 24
$586.0M
$1.5B
Q2 24
$600.2M
$1.4B
Q1 24
$609.7M
$1.4B
Total Assets
ARVN
ARVN
OSG
OSG
Q4 25
$2.2B
Q3 25
$844.3M
$2.1B
Q2 25
$8.5B
Q1 25
$1.0B
$8.3B
Q4 24
$1.1B
$8.1B
Q3 24
$1.2B
$9.3B
Q2 24
$1.3B
$8.2B
Q1 24
$1.2B
$8.4B
Debt / Equity
ARVN
ARVN
OSG
OSG
Q4 25
0.16×
Q3 25
0.00×
Q2 25
Q1 25
0.00×
Q4 24
0.00×
0.00×
Q3 24
0.00×
0.35×
Q2 24
0.00×
0.38×
Q1 24
0.00×
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARVN
ARVN
OSG
OSG
Operating Cash FlowLast quarter
$-59.1M
$-52.3M
Free Cash FlowOCF − Capex
$-59.2M
FCF MarginFCF / Revenue
-141.3%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-361.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARVN
ARVN
OSG
OSG
Q4 25
$-52.3M
Q3 25
$-59.1M
$-41.2M
Q2 25
$2.1M
Q1 25
$-88.9M
$-12.6M
Q4 24
$-84.1M
$762.0K
Q3 24
$-128.0M
$48.9M
Q2 24
$50.3M
$20.4M
Q1 24
$-97.5M
$7.1M
Free Cash Flow
ARVN
ARVN
OSG
OSG
Q4 25
Q3 25
$-59.2M
Q2 25
Q1 25
$-89.3M
Q4 24
$-84.4M
Q3 24
$-128.7M
Q2 24
$49.6M
Q1 24
$-97.6M
FCF Margin
ARVN
ARVN
OSG
OSG
Q4 25
Q3 25
-141.3%
Q2 25
Q1 25
-47.3%
Q4 24
-142.6%
Q3 24
-125.7%
Q2 24
64.8%
Q1 24
-385.8%
Capex Intensity
ARVN
ARVN
OSG
OSG
Q4 25
Q3 25
0.2%
Q2 25
Q1 25
0.2%
Q4 24
0.5%
Q3 24
0.7%
Q2 24
0.9%
Q1 24
0.4%
Cash Conversion
ARVN
ARVN
OSG
OSG
Q4 25
Q3 25
Q2 25
Q1 25
-1.07×
Q4 24
Q3 24
Q2 24
Q1 24
0.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARVN
ARVN

Segment breakdown not available.

OSG
OSG

Other$28.7M43%
Specialty Property Casualty Program$23.1M34%
Accident Health$9.6M14%
Specialty Automobile$3.1M5%
Niche Specialty Risks$2.4M4%

Related Comparisons